WBD shareholders approve the Paramount mega-merger — but reject David Zaslav's pay package

WBD shareholders approved the Paramount Skydance acquisition at a special meeting, moving the $111 billion merger one step closer to closing. Investors also voted against the executive pay package, including a potential award of nearly $887 million for CEO David Zaslav, though that vote is non-binding. The deal still needs regulatory approval in the U.S. and abroad, with antitrust scrutiny a key remaining risk.

Analysis

The equity vote clears a key signaling hurdle, but the real market-moving gate is now regulatory timing, not deal intent. That shifts the trade from a binary arb/approval setup toward a longer-dated optionality trade on process risk: the nearer-term path of least resistance is headline accumulation, while the farther-out risk is that state AGs or foreign regulators force concessions that erode synergy value or stretch closing by quarters.

Second-order, the vote against compensation matters because it weakens management’s political capital just as the combined company will need to defend cost cuts, content rationalization, and likely layoffs. That creates asymmetric execution risk: even if the deal closes, the first 6-12 months could see labor noise, talent churn, and higher integration friction, which tends to hit media multiples before any synergy benefit is visible.

The market is probably underpricing the possibility that the deal is approved with material behavioral remedies rather than outright blocked. Those remedies would not kill the merger but could impair the strategic logic by limiting channel bundling, distribution leverage, or future M&A flexibility. In that scenario, the loser is the merged asset base’s long-term optionality, while the relative winner may be larger alternative platforms that avoid the distraction and can poach talent and content relationships during the integration window.

Contrarianly, the biggest near-term upside may be in volatility rather than direction: a stock move up on approval headlines is likely to be offset by incremental regulatory noise over the next 1-3 months. The consensus seems focused on whether the deal closes; the more important question is what the post-close company is allowed to do, because that determines whether the transaction is value-accretive or just a slower, more heavily levered consolidation story.

Key Decisions for Investors

• WBD: trim long exposure into approval-strength headlines; use any 5-10% pop to reduce position size, as upside from here is more likely path-dependent on regulatory mitigation than on the shareholder vote itself.
• WBD: buy 3-6 month downside protection via put spreads around key regulatory milestones; risk/reward favors hedging because a material remedies scenario can compress the stock even if the deal survives.
• Pairs trade: long NFLX / short WBD on a 1-3 month horizon if regulatory scrutiny intensifies; NFLX benefits from any delay or dilution of the merger’s strategic rationale, while WBD carries execution and governance overhang.
• If the spread between WBD and implied deal value widens on antitrust chatter, consider a merger-arb style long WBD only if regulatory probability remains >70%; otherwise the expected value is dominated by tail risk, not spread carry.